Safety assessment of probiotics for human use

被引:491
作者
Sanders, Mary Ellen [1 ]
Akkermans, Louis M. A. [2 ]
Haller, Dirk [3 ]
Hammerman, Cathy [4 ]
Heimbach, James [5 ]
Hoermannsperger, Gabriele [3 ]
Huys, Geert [6 ]
Levy, Dan D. [7 ]
Lutgendorff, Femke [8 ]
Mack, David [9 ,10 ]
Phothirath, Phoukham [11 ]
Solano-Aguilar, Gloria [12 ]
Vaughan, Elaine [13 ]
机构
[1] Dairy & Food Culture Technol, Centennial, CO 80122 USA
[2] Univ Med Ctr, Dept Surg, Utrecht, Netherlands
[3] Tech Univ Munich, Ctr Diet & Dis, ZIEL Res Ctr Nutr & Food Sci, Freising Weihenstephan, Germany
[4] Shaare Zedek Med Ctr, Dept Neonatol, Jerusalem, Israel
[5] JHEIMBACH LLC, Port Royal, VA USA
[6] Univ Ghent, Fac Sci, Lab Microbiol, Ghent, Belgium
[7] US FDA, Div Dietary Supplement Programs, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[8] Univ Med Ctr, Dept Surg, Utrecht, Netherlands
[9] Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada
[10] Univ Ottawa, Ottawa, ON, Canada
[11] Nestle Res Ctr, Lausanne, Switzerland
[12] ARS, Diet Genom & Immunol Lab, BHNRC, USDA, Beltsville, MD USA
[13] Unilever R&D, Vlaardingen, Netherlands
关键词
safety; probiotic; lactobacillus; bifidobacterium; FDA; Health Canada; QPS; PROSAFE; antibiotic resistance; LOW-BIRTH-WEIGHT; LACTOBACILLUS-RHAMNOSUS-GG; D-LACTIC ACIDOSIS; POSTOPERATIVE INFECTIOUS COMPLICATIONS; PREVENT NECROTIZING ENTEROCOLITIS; CULTURE-INDEPENDENT ANALYSIS; INTESTINAL EPITHELIAL-CELLS; PLACEBO-CONTROLLED TRIAL; SHORT-BOWEL SYNDROME; 1ST; MONTHS;
D O I
10.4161/gmic.1.3.12127
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The safety of probiotics is tied to their intended use, which includes consideration of potential vulnerability of the consumer or patient, dose and duration of consumption, and both the manner and frequency of administration. Unique to probiotics is that they are alive when administered, and unlike other food or drug ingredients, possess the potential for infectivity or in situ toxin production. Since numerous types of microbes are used as probiotics, safety is also intricately tied to the nature of the specific microbe being used. The presence of transferable antibiotic resistance genes, which comprises a theoretical risk of transfer to a less innocuous member of the gut microbial community, must also be considered. Genetic stability of the probiotic over time, deleterious metabolic activities, and the potential for pathogenicity or toxicogenicity must be assessed depending on the characteristics of the genus and species of the microbe being used. Immunological effects must be considered, especially in certain vulnerable populations, including infants with undeveloped immune function. A few reports about negative probiotic effects have surfaced, the significance of which would be better understood with more complete understanding of the mechanisms of probiotic interaction with the host and colonizing microbes. Use of readily available and low cost genomic sequencing technologies to assure the absence of genes of concern is advisable for candidate probiotic strains. The field of probiotic safety is characterized by the scarcity of studies specifically designed to assess safety contrasted with the long history of safe use of many of these microbes in foods.
引用
收藏
页码:164 / 185
页数:22
相关论文
共 199 条
[1]   Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock [J].
Abdelrahman, M ;
Sivarajah, A ;
Thiemermann, C .
CARDIOVASCULAR RESEARCH, 2005, 65 (04) :772-781
[2]   Probiotics in prevention of IgE-associated eczema:: A double-blind, randomized, placebo-controlled trial [J].
Abrahamsson, Thomas R. ;
Jakobsson, Ted ;
Bottcher, Malin Fageras ;
Fredrikson, Mats ;
Jenmalm, Maria C. ;
Bjorksten, Bengt ;
Oldaeus, Goran .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (05) :1174-1180
[3]  
Alander M, 1999, APPL ENVIRON MICROB, V65, P351
[4]   Influence of the critically ill state on host-pathogen interactions within the intestine: Gut-derived sepsis redefined [J].
Alverdy, JC ;
Laughlin, RS ;
Wu, LC .
CRITICAL CARE MEDICINE, 2003, 31 (02) :598-607
[5]   Role of the gut in the course of severe acute pancreatitis [J].
Ammori, BJ .
PANCREAS, 2003, 26 (02) :122-129
[6]  
[Anonymous], OUYOU YAKURI
[7]  
[Anonymous], RISK ASSESSMENT USE
[8]  
[Anonymous], OPINION STEERING COM
[9]  
[Anonymous], BRAIN DEV
[10]  
[Anonymous], 2002, OPINION SCI COMMITTE